Why Global Blood Therapeutics Surged 10.7% Higher

After the company reported that a phase 3 trial of its most advanced clinical-stage drug panned out, shares in Global Blood Therapeutics (NASDAQ: GBT) rallied 10.7% on Wednesday.Global Blood Therapeutics is developing Voxelotor, an oral, once-daily therapy for sickle cell disease (SCD), a life-threatening chronic disease that can starve organs of blood and cause stroke.IMAGE SOURCE: GETTY IMAGES.Continue reading

 

Welcome to Wopular!

Welcome to Wopular

Wopular is an online newspaper rack, giving you a summary view of the top headlines from the top news sites.

Senh Duong (Founder)
Wopular, MWB, RottenTomatoes

Subscribe to Wopular's RSS Fan Wopular on Facebook Follow Wopular on Twitter Follow Wopular on Google Plus

MoviesWithButter : Our Sister Site

More Business News